New Delhi, Sept. 25 -- The new age semaglutide- and tirzepatide-based weight-loss jabs such as Mounjaro and Ozempic couldn't have come any sooner to India as the country faces a twin engine public health threat of obesity and diabetes. Now, there's more good news. A new daily pill containing the drug orforglipron developed by Eli Lilly, the makers of Mounjaro, has shown promise in the latest trials. In a trial of 3,127 adults, 20% of the people who took the once-a-day tablet for 72 weeks lost 20% or more of their body weight. Orforglipron is a glucagon-like peptide-1 (GLP-1) agonist, a type of medication that helps lower blood sugar levels, slows the digestion of food and reduces appetite. The findings of the Eli Lilly trial were publishe...